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Background: The introduction of Antiretroviral Therapy (ART) has brought a remarkable reduction in HIV-related
mortality and morbidity both in adults and children living with HIV/AIDS. Adherence to ART is the key to the
successful treatment of patients as well as containment of drug resistance. Studies based on caregivers’ report have
shown that adherence to ART among children is generally good. However, subjective methods such as caregivers’
report are known to overestimate the level of adherence. This study determined the rate of adherence and its
predictors using unannounced home-based pill count and compared the result with caregivers’ report in a tertiary
referral hospital in Ethiopia.
Methods: A cross-sectional study was conducted between December 1, 2011 and January 30, 2012. The study
participants were 210 children on ART and their caregivers attending pediatric ART clinic of Tikur Anbessa Hospital
(TAH), Addis Ababa University. Caregivers were interviewed at the ART clinic using a structured questionnaire. Then,
unannounced home-based pill count was done 7 days after the interview.
Results: Caregiver-reported adherence in the past 7 days prior to interview was 93.3%. Estimated adherence using
unannounced home-based pill count was found, however, to be 34.8%. On multivariate logistic regression model,
children with married [aOR = 7.85 (95% CI: 2.11,29.13)] and widowed/divorced [aOR = 7.14 (95% CI: 2.00,25.46)]
caregivers, those who were not aware of their HIV sero-status [aOR = 2.35 (95% CI:1.09, 5.06)], and those with
baseline WHO clinical stage III/IV [OR = 3.18 (95% CI: 1.21, 8.40] were more likely to adhere to their ART treatment.
On the other hand, children on d4T/3Tc/EFV combination [OR = 0.10 (95% CI: 0.02, 0.53)] were less likely to adhere
to their treatment. Caregivers’ forgetfulness and child refusal to take medication were reported as the major reasons
for missing doses.
Conclusion: The level of adherence based on unannounced home-based pill count was unacceptably low.
Interventions are urgently needed to improve adherence to ART among children at TAH. Besides, a longitudinal
study measuring adherence combined with clinical parameters (viral load and CD4 count) is needed to identify a
simple and reliable measure of adherence in the study area.
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HIV/AIDS is one of the most devastating pandemics hu-
manity has ever faced. Globally, about 34 million people
were living with the virus in 2010 [1]. In the same year,
children contributed to 10% of the total infected. Sub-
Saharan Africa remains the most hard-hit region
accounting for 68% of the total global burden [1]. Al-
though the prevalence is relatively low, Ethiopia carries
one of the largest HIV-infected populations in the world.
Out of the 1.1 million people living with HIV, about
72,000 were reported to be children [2].
In an effort to curb the epidemics as well as to im-
prove the quality of life among HIV-infected people,
multiple strategies including treatment of patients with
ART have been implemented worldwide. The introduc-
tion of ART has resulted in a remarkable reduction of
HIV-related mortality and morbidity [3-6] as a result of
rapid immunological restoration [3,7,8] and viral sup-
pression [3,8].
However, ART provision has major challenges. Despite
efforts made over the last decade, universal access to
ART especially in low income countries remains low:
only half of adults and a quarter of children eligible for
ART have started treatment [1]. Among those on ART,
retention as well as adherence to therapy remains to be
major obstacles for the successful treatment of HIV-
infected patients. Adherence to ART is the key to
achieving optimal therapeutic effects [9]. Studies indicate
that poor adherence is associated with virologic failure
[10,11] and increased mortality [12].
Hence, unacceptably high level of virologic failure
[10,13,14], limited access to second line drugs in low in-
come countries and the public risk of transmitted
resistance as HIV infected children living into adoles-
cence become engaged in sexual relationships make
maintaining adherence among children crucial [15]. For
optimal therapeutic effect and to minimize HIV drug re-
sistance, patients should have at least ≥ 95% adherence
to ART [6,11,16].
Designing strategies for maintaining optimal level of
adherence among children is an essential step towards
ensuring treatment success. However, this task requires
careful assessment of the status of level of adherence
and its predictors among the target population [6,17]. In
pediatric patients, adherence is more complex as it
involves factors related to children, caregivers, family,
regimen, society and culture [15,17], and measuring ad-
herence remains a challenge since there is no single
method that is reliable and simple [15].
Globally, the level of adherence to ART among HIV
infected children varied from 49% to 100% [18] depend-
ing on the settings and the methods used. The most fre-
quently used measure of adherence in children is self or
caregivers’ report, and the highest level of adherence(79.5-100%) emerged from such measurements [18]. Pre-
vious studies among Ethiopian children [19] and adults
[20,21] reported a high level of adherence to ART using
self /caregivers’ report. However, self or caregivers’ re-
port method alone, although simple, is subjective and
subject to social desirability [17] and recall bias. Pill
count is a more objective method to assess medication
adherence and is recommended as a standard for clinical
practice [22]. Therefore, this study looks into the level of
adherence and associated factors among pediatric HIV
patients taking ART in a pediatric ART clinic using un-
announced home-based pill count and compares the re-
sult to caregivers’ reported adherence.
Methods
Study area
The study was conducted at the pediatric ART clinic of
TAH, Addis Ababa University. TAH, located in Addis
Ababa, is the single largest referral and tertiary level
teaching hospital in Ethiopia. Patients are referred to this
hospital from other health institutions across the coun-
try. After the government launched free ART in 2005,
the hospital started to provide the service to people liv-
ing with HIV/AIDS including children. The hospital has
separate ART clinics for adults and children.
The hospital provides both first line and second line
drug regimens. First line regimens that children
were taking included 4a = d4T/3Tc/NVP (Stavudine,
Lamivudine, Nevirapine), 4b = d4T/3Tc/EFV (Stavudine,
Lamivudine, Efavirenz), 4c = AZT/3Tc/NVP (Zidovu-
dine, Lamivudine, Nevirapine), and 4d = AZT/3Tc/EFV
(Zidovudine, Lamivudine, Efavirenz). Some children
were also on the following second line regimens: ABC/
ddi/LPv/r (Abacavir, Didanosine, retonavir enhanced
Lopinavir), AZT/3Tc/LPv/r (Zidovudine, Lamivudine,
retonavir enhanced Lopinavir) and D4T/3TC/LPv/r
(Stavudine, Lamivudine, retonavir enhanced Lopinavir).
The only liquid formulation available during the study
period was LPv/r and only one child was taking this for-
mulation as a component of D4T/3TC/LPv/r. The rou-
tine laboratory tests included CD4 count, haemoglobin
and blood chemistry such as liver function tests. Among
these, CD4 count was done every 6 months and the rest
were done on the basis of clinical conditions of children.
Study design and study participants
A cross-sectional study was conducted between December
1, 2011 and January 30, 2012. Since the initiation of free
ART programme, a total of 1152 HIV positive children
were registered at the pediatric ART clinic of the hospital.
Of these children, 751 were started on treatment and 554
of them were on active follow-up during data collection.
All children (<15 years) on ART for at least three months
and their caregivers were consecutively included until
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age, those younger than 3 months as well as those living
out of Addis Ababa were excluded. Sample size of 210
was calculated using the formula for estimation of single
population proportion with 95% CI, 5% margin of error,
estimated adherence level of 86.9% [19] and a 20% non-
response rate.Method of data collection
Data collection was done using a pre-tested, structured
questionnaire addressing demographic, socioeconomic
and disclosure variables of caregivers and children, as
well as health care providers and health care system var-
iables. Nine questions were posed to assess knowledge
of caregivers about the ART regimen their children were
taking and the median score was taken as a cut-off to
classify caregivers as having good or poor knowledge.
Available clinical (WHO stage) and immunological (CD4
count) data of children were extracted from records.
Caregivers were interviewed during routine clinic ap-
pointments in a separate room. Care givers’ home ad-
dresses were recorded at the time of interview after
getting permission for a home visit; however, caregivers
were not informed regarding pill count until home visit
was made to avoid bias. Home-based unannounced pill
count was conducted 7 days after interview. To make
sure caregivers received the prescribed number of pills
from the pharmacy, pill count was done immediately
after pills were dispensed. Subsequently, caregivers were
instructed to use only the currently dispensed pills and
not any pills left at home. Pills left at home were
counted separately and were not included in calculating
adherence rate. Interview and pill count were done by a
trained nurse and one of the authors supervised data
collection.Operational definitions
Adherence – Adherence to a medication is generally de-
fined as the extent to which patients take medications as
prescribed by their health care providers. In HIV
treatment, adherence < 95% is associated with virologic
failure [6,11], opportunistic infections and deaths [23],
and therefore, in this study a child was said to be adher-
ent if he/she took ≥95% of the prescribed doses for one
week prior to the interview or the pill count.
Caregiver – Parent/guardian or person in charge of
routinely administering antiretroviral drugs to children
on ART.
Good knowledge- If care givers answer 7–9 questions
correctly
Poor knowledge- less than 7 questions answered
correctly
Biological parents - mother or father of the childNon- biological parents - Relatives, or those who
adopted the child
Baseline CD4 count: CD4 count done when a child
started ART
Current CD count: CD4 count done within 6 months
of data collection
Data management and analysis
Data were checked manually, computerized using
EPiData version 3.0 and exported to SPSS version 20 for
analysis. Chi-square test was used to assess association
between adherence and independent variables. The per-
cent of adherence was calculated by dividing the number
of doses taken in one week by the total number of doses
prescribed for that week. Multivariate logistic regression
was done to identify factors independently associated
with ART adherence. The association of predictor vari-
ables with the dependent variable was described by using
95% confidence interval (CI) and adjusted odds ratio
(aOR). A p-value of < 0.05 was considered statistically
significant.
Ethics statement
The study was approved by the Institutional Ethical Re-
view Board of Aklilu Lemma Institute of Pathobiology
(ALIPB193/2004), Institutional Ethical Review Board of
Medical Faculty, Addis Ababa University (085/11/ped)
and Armauer Hansen Research Institute and All Africa
Leprosy, Tuberculosis and Rehabilitation Training
Centre Ethical Review Committee (Po09/12). Written in-
formed consent was obtained from all caregivers and
verbal assent was obtained from children who were
aware of their sero-status.
Results
Socio-demographic characteristics of caregivers and
children
A total of 238 primary caregivers were interviewed of
whom 28 refused home visit, making the response rate
for pill count 88%. Hence, 210 caregivers were included
in the final analysis. The median age of caregivers was
38(IQR 30.8-49) years; and the majority (84.8%) of them
were females. Of the 210 children, 109 (51.9%) were
males and the median age was 11 (IQR 8–13) years, the
vast majority (74.8%) being 9 years or older. The
majority of the caregivers were literate and with a
monthly income less than 30 USD. More than half of
the caregivers were biological parents of the children
(Table 1). Of the total caregivers, 139(66.2%) have good
level of knowledge regarding ART with a median know-
ledge score of 7(IQR 6–8). All of the caregivers were
able to correctly tell the right dose and frequency of pills
that their children were taking.
Table 1 Socio-demographic characteristics of caregivers and children on ART, TAH, Addis Ababa, 2012
Characteristics Non-adherent Adherent p-value
number (%) number (%)
Caregivers’ sex
Male 20 (62.5) 12 (37.5) 0.77
Female 116 (65.2) 62 (34.8)
Caregivers’ age
18-40 83 (63.4) 48 (36.6)
41-65 38 (63.3) 22 (36.7)
66-90 15 (78.9) 4 (21.1) 0.40
Caregivers’ marital status
Single 24 (82.8) 5 (17.2)
Married 48 (61.5) 30 (38.5) 0.09
Widowed/divorced 64 ( 62.1) 39 (37.9)
Caregivers’ religion
Orthodox 97 (66.0) 50 (34.0)
Muslim 21 (61.8) 13 (38.2)
Protestant 18 (62.1) 11 (37.9) 0.85
Caregivers’ education
Illiterate 40 (69.0) 18 (31.0)
Elementary education 53 (65.4) 28 (34.6)
Secondary and above 43 (60.6) 28 (39.4) 0.60
Caregivers’ occupation
House wife 41 (62.1) 25 (37.9)
Employed 25 (69.4) 11 (30.6) 0.82
Daily laborer 38 (62.3) 23 (37.7)
Others‡ 32 (68.1) 15 (31.9)
Monthly income of care givers†
<30 USD 100 (64.9) 54 (35.1)
≥30 USD 36 (64.3) 20 (35.7) 0.93
Caregivers’ relation to child
Biological 76 (62.8) 45 (37.2)
Non-biological 60 (67.4) 29 (32.6) 0.49
Age of child
1-5 12 (92.3) 1 (7.7)
6-8 24 (60) 16 (40) 0.09
9-14 100 (63.7) 57 (36.3)
Sex of child
Male 69 (63.3) 40 (36.7)
Female 67 (66.3) 34 (33.7) 0.65
Children knew their HIV status
Yes 63 (70.8) 26 (29.2)
No 73 (57.7) 48 (42.3) 0.11
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Table 1 Socio-demographic characteristics of caregivers and children on ART, TAH, Addis Ababa, 2012 (Continued)
Received any support
Yes 52 (70.3) 22 (29.7)
No 84 (61.8) 52 (38.2) 0.218
†Exchange rate −1$ = 17.6 Ethiopian birr.
‡others: students, daily laborers.
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One hundred and ten (52.4%) caregivers reported that
they have disclosed their children’s HIV status to others
(71.8% disclosed to the family and 28.2% disclosed to the
community) and 89(42.4%) disclosed to the children
themselves. However, most (82.9%) of the caregivers
were not comfortable to give ART drugs to their chil-
dren in the presence of others.
Seventy-four (35.2%) of the caregivers had support
(mainly as food or cash) for their children from different
sources, notably from non-governmental organizations;
however, only 6(8.11%) reported that they were satisfied
with the support they had received. Regarding the types
of regimens children have been taking, 67.6% were either
on 4d (AZT/3TC/EFV) or 4c (AZT/3TC/NVP).
Clinical markers of children on ART
The median length of time on ART was 48 months
(IQR: 30–66 months). Based on review of clinical re-
cords, 79% of them were either in stage III or Stage IV
of WHO classification at baseline. At the time of treat-
ment initiation, median CD4 count was 265 (IQR: 179–
461) cells/mm3 whereas the current median CD4 count
was 617 (IQR: 451–855) cells/mm3. There was a signifi-
cant improvement in the current CD4 count compared
to the baseline CD4 count (Wilcoxon, p < 001). On
stratifying by age, the improvement remained statistically
significant [Wilcoxon, p = 0.005 (≤ 5 years) and p < 0.001
(above 5 years)].
Health care providers and health care system variables
The vast majority (93.3%) of children have been on ART
for at least one year. Eighty-one percent of the caregivers
reported that they had very good relationship with the
health providers at the ART clinic. Furthermore, 206
(98.1%) had open communication and got information
needed from health care providers, and 208 (99.1%) had
access to the pharmacy at any day of the week. Two
hundred and five of them (97.6%) were satisfied in the
scheduled appointment and 204 (97.1%) were satisfied
with their child’s health improvement.
Adherence to ART
Based on caregivers’ report, two-third (66.7%) of the
study participants had no history of missed doses ever
and 90% had no missed doses in the last one month. Atotal of 196 (93.3%) children were reported to have ad-
herence rate of at least 95% for the past 7 days before
interview. However, 96 (47.7%) caregivers reported that
medication had been taken several hours late on occa-
sions within the last week.
On unannounced home-based pill count, only 73
(34.8%) had adherence level of at least 95% which is
much less than the reported level of adherence (Figure 1).
The level of agreement between caregivers’ report and
unannounced pill count was poor (kappa = 0.032).
The median number of doses missed in one week was
1 (IQR: 0–2). Extra pills were counted during home visit
and 37.1% of children had no extra pills, whereas 56.3%
had 1 to 50 extra doses at home (Table 2). There was no
significant difference in the level of adherence between
those who had and who did not have extra doses at
home (p = 0.46).
When caregivers were asked regarding the type of
memory aid they used, the majority (67.1%) reported
that they used a watch as memory aid for giving medica-
tion. Caregivers’ forgetfulness (36.4%) and child refusal
to take medication (27.3%) were reported to be the
major reasons for missing doses and delayed ingestion of
their pills (Figure 2).
On multivariate logistic regression, children with a
married [aOR = 7.85 (95% CI: 2.11, 29.13)] or widowed/
divorced caregiver [aOR = 7.14 (95% CI: 2.00, 25.46)]
were more likely to adhere to their ART treatment when
compared to those with single caregivers. Similarly, chil-
dren who did not know their HIV sero-status were more
likely to adhere to their treatment [aOR = 2.35 (95% CI:
1.09, 5.06)] compared to those who knew their sero-
status. Those children with baseline WHO clinical stage
III/IV were 2.78 times [OR = 3.18 (95% CI: 1. 21, 8.40)]
more adherent to their ART treatment when compared
to those with stage I/II. On the other hand, children on
d4T/3Tc/EFV combination were less adherent than
those who were on d4T/3Tc/NVP combination [OR =
0.10 (95% CI: 0.02, 0.53)] (Table 3).
Discussion
Unlike previous studies in Ethiopia, this study deter-
mined the level of adherence and its predictors using
unannounced home-based pill count and compared the
result with caregivers’ report. Based on caregivers’ re-
port, the estimated adherence rate in the last 7 days
Figure 1 Children’s level of adherence to ART estimated by unannounced home-based pill count, TAH, Addis Ababa, 2012.
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givers’ reported adherence level in a similar setting [19];
however, using unannounced home-based pill count, the
adherence rate (34.8%) was unacceptably low. There is
an enormous discrepancy between optimal adherence
rate (≥95%) estimated by caregivers’ report (93.3%) and
unannounced home-based pill count (34.8%). Similar
studies elsewhere reported discrepancies between un-
announced home-based pill count and caregivers’ report.
For example, a study in Uganda among children on ARTTable 2 Missed doses, extra doses and adherence on
unannounced home-based pill count of children on ART
at TAH, Addis Ababa, 2012
Characteristics Number (%)





Extra doses at home







Adherent 73 (34.8)reported adherence rate of 89% and 94% using self-
report and clinic based pill count, respectively; however,
on subsequent unannounced pill count, only 72% of
children were found to be adherent to their treatment
[24]. Similarly, a study in Tanzania [25] among adults on
ART revealed that 98% and 93% of patients were
adherent based on self-report and hospital pill count,
respectively but only 58% were found adherent on un-
announced home visit pill count. Another study from
South Africa reported that objective methods gave lower
levels of adherence [26] implying that subjective
methods such as caregivers’ report overestimate levels of
adherence.
The level of adherence estimated by unannounced
home-based pill count in our study is very low as op-
posed to many other studies. However, three studies
using objective methods like medication event monitor-
ing system (MEMS) reported very low (31-39%) adher-
ence rates [26-28] which are comparable to our findings.
The difference in the level of adherence among studies
could be explained by differences in the methods used.
Almost all studies which used subjective methods
reported a high level of adherence compared to those
that used objective methods. Studies [26-28] have shown
that high levels of adherence as measured by objective
methods correlate well with virologic suppression show-
ing that objective methods might reflect the actual level
of adherence.
Children skip doses for a number of reasons. In this
study, caregivers’ forgetfulness was reported as a major
reason (36.4%) for skipping doses which is in agreement
with other similar studies [19,29]. The vast majority of
Figure 2 Reasons for missing doses mentioned by care givers of children on ART follow up at Tikur Anbessa Hospital, Addis
Ababa, 2012.
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tiple responsibilities in meeting daily life demands, they
could easily forget to make sure their children have
taken their pills as scheduled. Moreover, child refusal to
take medication (27.3%) and child illness (12.1%) were
reported to be the other major reasons for skipping
doses. These same reasons were mentioned in a review
of studies among adults and children [6].
A number of factors have been reported as predictors
of non-adherence among children on ART. In this study,
children with married and widowed/divorced caregivers
were significantly more adherent when compared to
children with single caregivers, which is in agreement to
a report from Nigeria [30]. Married caregivers might get
support from their spouse in providing care to their chil-
dren. Besides, widowed and divorced caregivers might
be more experienced in handling children as compared
to single caregivers.
The association between awareness of sero-status and
adherence remains controversial. In this study like many
other studies [19,31,32], children who were aware of
their HIV status were less adherent than those who were
not. However, other studies [15] reported that lack of
disclosure of their HIV sero-status among children pre-
dicted non- adherence. Children who are aware of their
sero-status might deny, feel hopelessness and skip treat-
ment doses until they accept their HIV sero-status; and
the observed difference across studies might be related
to the extent and duration of counseling offered to chil-
dren. Those children who have been getting regular
counseling and support might accept their sero-statusand be more adherent to their treatment than those who
do not get proper counseling. Nevertheless, investigation
of the importance of HIV sero-status disclosure to chil-
dren is essential to settle these contradictory results.
The association of clinical condition of children at ini-
tiation of ART and treatment adherence is not well
established. Some studies found an association between
worse adherence and advanced disease [15] which is
contrary to our finding. In this study, children who were
in WHO stage III or IV at baseline were more adherent
to their medication compared to those in stage I or II. A
study from Uganda reported that those children who
were hospitalized twice or more prior to starting ART
had better treatment adherence levels [24]. Those chil-
dren with advanced disease might be more eager to get
well and this might be a motive for better adherence to
their treatment.
Children taking d4T/3Tc/EFV combination were less
likely to adhere than those children on d4T/3Tc/NVP
combination. Although every drug has its own adverse
effect, lower adherence on children on Efavirenz com-
bination in this study is probably due to its serious side
effects including neuropsychological symptoms, such as
bad dreams, dizziness, depression, anxiety, hallucina-
tions, aggressive behavior, and suicidal ideation [33].
A cross-sectional study design was employed in this
study and its limitations especially recall bias should be
appreciated. Besides, participants were included con-
secutively when they came for their regular clinic ap-
pointment and this might have introduced selection
bias. This study was done in a season of holidays that
Table 3 Predictors of ART adherence among children at TAH, Addis Ababa, 2012
Characteristics Non-adherent Adherent Crude OR Adjusted OR
number number (95% CI) (95% CI)
Care givers’ marital status
Single 24 5 Reference Reference
Married 48 30 3.00 (1.03, 8.71) 7.85 (2.11, 29.13)*
Widowed/ Divorced 64 39 2.93 (1.03, 8.30) 7.14 (2.00, 25.46)*
Children knew their HIV status
Yes 63 26 Reference Reference
No 73 48 1.59 (0.89, 2.86) 2.35 (1.09, 5.06)*
Regimen type
4a = d4T/3TC/NVP 26 14 Reference Reference
4b = d4T/3TC/EFV 17 2 0.22 (0.04, 1.09) 0.10 (0.02, 0.53)*
4c = AZT/3TC/NVP 32 26 1.51 (0.66, 3.46) 1.50 (0.54, 4.13)
4d = AZT/3TC/EFV 53 31 1.09 (0.50, 2.39) 0.63 (0.24, 1.67)
Others$ 8 1 0.23 (0.03, 2.05) 0.11 (0.01, 1.23)
Duration on ART
<12 months 13 1 Reference Reference
≥ 12 months 123 73 7.71 (0.99,60.20) 8.37 (0.91,77.32)
Baseline WHO stage
Stage I and II 34 10 Reference Reference
Stage III and IV 102 64 2.13 (0.99,4.61) 3.18 (1,21,8.40)*
Baseline CD4
≤200 44 25 Reference Reference
201–500 60 37 1.09 (0.57,2.06) 0.81 (0.37,1.75)




Variables included in the logistic regression model were age and sex of child, caregivers’ age, caregivers’ sex, caregivers’ education and income.
$Others: ABC/ddi/LPv/r, AZT/3Tc/LPv/r and D4T/3TC/LPv/r.
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to give medications to their children in front of others
to avoid stigma and this might have underestimated the
level of adherence. In this study, it was not possible to
assess the clinical relevance of adherence among chil-
dren. Besides, a point adherence level may not reflect
the actual long term adherence, implying the need for
longitudinal studies.
Conclusion
In this study, there was a major difference in the level of
adherence estimated by caregivers’ report and un-
announced home-based pill count. The level of adher-
ence estimated by unannounced home-based pill count
was found to be unacceptably low. Interventions towards
improving adherence to ART among children at TAH
are urgently needed. Moreover, children with single
caregivers, those who were aware of their sero-status,
those with baseline WHO clinical stage I/II and thoseon d4t/3TC/EFV combination need special attention to
improve their level of adherence to their medication.
A longitudinal study measuring adherence combined
with clinical parameters (viral load and CD4 count) is
needed to identify a simple and reliable measure of ad-
herence in the study area.
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